JP2018533579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533579A5 JP2018533579A5 JP2018522081A JP2018522081A JP2018533579A5 JP 2018533579 A5 JP2018533579 A5 JP 2018533579A5 JP 2018522081 A JP2018522081 A JP 2018522081A JP 2018522081 A JP2018522081 A JP 2018522081A JP 2018533579 A5 JP2018533579 A5 JP 2018533579A5
- Authority
- JP
- Japan
- Prior art keywords
- poly
- particles
- mucus
- polymer
- permeable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 claims description 49
- 229920000642 polymer Polymers 0.000 claims description 25
- 210000003097 mucus Anatomy 0.000 claims description 23
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 210000000981 epithelium Anatomy 0.000 claims description 8
- 239000000032 diagnostic agent Substances 0.000 claims description 7
- 229940039227 diagnostic agent Drugs 0.000 claims description 7
- 230000000069 prophylactic effect Effects 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 229920001273 Polyhydroxy acid Polymers 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 230000000149 penetrating effect Effects 0.000 claims description 3
- 210000001533 respiratory mucosa Anatomy 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229920005689 PLLA-PGA Polymers 0.000 claims description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 2
- 229920001267 Poly(D,L-lactide-co-PPO-co-D,L-lactide) Polymers 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 238000009792 diffusion process Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920001245 poly(D,L-lactide-co-caprolactone) Polymers 0.000 claims description 2
- 229920001253 poly(D,L-lactide-co-caprolactone-co-glycolide) Polymers 0.000 claims description 2
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
- 239000002745 poly(ortho ester) Substances 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- -1 polyethylene Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 230000035515 penetration Effects 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000003607 modifier Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248432P | 2015-10-30 | 2015-10-30 | |
| US62/248,432 | 2015-10-30 | ||
| PCT/US2016/059661 WO2017075565A1 (en) | 2015-10-30 | 2016-10-31 | Mucus penetrating particles with high molecular weight and dense coatings |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018533579A JP2018533579A (ja) | 2018-11-15 |
| JP2018533579A5 true JP2018533579A5 (enExample) | 2019-12-12 |
Family
ID=57288512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522081A Pending JP2018533579A (ja) | 2015-10-30 | 2016-10-31 | 高分子量かつ密な被覆を有する粘液浸透粒子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10668025B2 (enExample) |
| EP (1) | EP3368008A1 (enExample) |
| JP (1) | JP2018533579A (enExample) |
| KR (1) | KR20180075650A (enExample) |
| CN (1) | CN108472250A (enExample) |
| AU (1) | AU2016343840A1 (enExample) |
| CA (1) | CA3003733C (enExample) |
| WO (1) | WO2017075565A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8957034B2 (en) * | 2004-01-28 | 2015-02-17 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| WO2012076877A1 (en) | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| AU2012351994B2 (en) * | 2011-12-14 | 2015-11-05 | The Johns Hopkins University | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
| WO2019175290A1 (en) | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis or cannabis derived compositions for promoting cessation of chemical dependence |
| CA3110773C (en) | 2018-09-11 | 2023-02-28 | Lead Biotherapeutics Ltd. | Mucoadhesive dispersion nanoparticle system and method for production the same |
| EP4164598A1 (en) * | 2020-06-11 | 2023-04-19 | Janssen Biotech, Inc. | Controlled release of self-embedding particles for localized drug delivery |
| JP2022130270A (ja) * | 2021-02-25 | 2022-09-06 | シンバイオシス株式会社 | 腸管吸収用補助剤及びその利用方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US8957034B2 (en) * | 2004-01-28 | 2015-02-17 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| ES2360538T3 (es) * | 2006-09-08 | 2011-06-06 | Johns Hopkins University | Composiciones para aumentar el transporte a través de moco. |
| WO2012039979A2 (en) * | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| CA2816977C (en) * | 2010-11-05 | 2019-10-29 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
| ES2385995B2 (es) * | 2011-01-10 | 2013-05-21 | Universidade De Santiago De Compostela | Nanocápsulas con cubierta polimérica |
| AU2012351994B2 (en) * | 2011-12-14 | 2015-11-05 | The Johns Hopkins University | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
| KR101811917B1 (ko) * | 2012-01-19 | 2017-12-22 | 더 존스 홉킨스 유니버시티 | 점액 침투 강화를 나타내는 나노 입자 제형 |
| NZ741873A (en) * | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| KR102154880B1 (ko) | 2012-05-03 | 2020-09-10 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
| HK1208377A1 (en) * | 2012-05-04 | 2016-03-04 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
-
2016
- 2016-10-31 KR KR1020187015274A patent/KR20180075650A/ko not_active Withdrawn
- 2016-10-31 CN CN201680075874.0A patent/CN108472250A/zh active Pending
- 2016-10-31 JP JP2018522081A patent/JP2018533579A/ja active Pending
- 2016-10-31 EP EP16795204.3A patent/EP3368008A1/en not_active Withdrawn
- 2016-10-31 US US15/771,961 patent/US10668025B2/en active Active
- 2016-10-31 CA CA3003733A patent/CA3003733C/en active Active
- 2016-10-31 AU AU2016343840A patent/AU2016343840A1/en not_active Abandoned
- 2016-10-31 WO PCT/US2016/059661 patent/WO2017075565A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533579A5 (enExample) | ||
| Pramanik et al. | Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases | |
| AU2018202074B2 (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
| Chenthamara et al. | Therapeutic efficacy of nanoparticles and routes of administration | |
| US20210196829A1 (en) | Nanoparticles with enhanced mucosal penetration or decreased inflammation | |
| Zhong et al. | Effect of the route of administration and PEGylation of poly (amidoamine) dendrimers on their systemic and lung cellular biodistribution | |
| US20140099379A1 (en) | Bio-compatible nano and microparticles coated with stabilizers for pulmonary application | |
| CN108472250A (zh) | 高分子量粘液穿透颗粒和致密涂层 | |
| WO2016128591A1 (es) | Procedimiento de obtención de una composición farmacéutica de nanopartículas poliméricas para el tratamiento del dolor neuropático producido por compresión nerviosa periférica | |
| Usharani et al. | Current nanotechnological strategies using lipids, carbohydrates, proteins and metal conjugates-based carrier systems for diagnosis and treatment of tuberculosis—A review | |
| Remya et al. | Formulation, development, and characterization of cilnidipine loaded solid lipid nanoparticles | |
| Bonde et al. | Lapatinib-loaded nanocolloidal polymeric micelles for the efficient treatment of breast cancer | |
| ES2872552T3 (es) | Nanopartículas poliméricas y métodos de preparación y de uso de las mismas | |
| CN119212725A (zh) | 聚合物纳米聚集体药物组合物及其用途 | |
| Teama et al. | Polymeric micelles for pulmonary drug delivery: a comprehensive review | |
| JP2017515839A5 (enExample) | ||
| Rathi et al. | Treatment of tuberculosis in nano era: recent avenues | |
| ALIPOUR et al. | Porogen effects on aerosolization properties of fluconazole loaded plga large porous particles | |
| Tanwar et al. | Nanoparticles: Scope in drug delivery | |
| JP2016539100A5 (enExample) | ||
| Shaikh et al. | Polymeric micelles in colorectal cancer therapy: A comprehensive review of nano-drug delivery strategies, copolymer types, physicochemical characteristics, and therapeutic applications | |
| Barji et al. | Formulation Development of Inhalable Dacomitinib Polymeric Nanoparticles for Non-Small Cell Lung Cancer Treatment | |
| WO2015051349A1 (en) | Treating metastatic cancer with micellular paclitaxel | |
| SAGAR et al. | FORMULATION AND EVALUATION OF DRY POWDER INHALABLE NANOPARTICLES FOR THE TREATMENT OF COVID-19 | |
| Kalčec et al. | Impact of serum albumin on binding ability of dopamine and L-dopa on differently coated gold nanoparticles |